findmyKOL

Matthew Cavender, MD

Basic profile

University of North Carolina at Chapel Hill

ORCIDNPI
RegionChapel Hill, NC · SoutheastSpecialtyInterventional CardiologyFocusCardiology
ActivityNot yet indexedfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Matthew Cavender is a Cardiology physician affiliated with University of North Carolina at Chapel Hill. OpenAlex indexes 197 publications with 11,163 citations (h-index 39). By OpenAlex citation count, this profile ranks in the top 10% of Interventional Cardiology profiles in the findmyKOL directory.

Overview

Scholarship

indexed output and impact (OpenAlex)
197publications

Distinct works indexed by OpenAlex, matched via ORCID.

11,163citations

Total citations across indexed works.

39h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
11companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

11 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    80.3%
    Statin22.2%
    Atorvastatin Calcium78%Rosuvastatin Calcium22%
    Part D89 patients
    Beta blocker13.8%
    Metoprolol Succinate71%Carvedilol20%Metoprolol Tartrate10%
    Part D<11 patients

    + 11 more classes in this area

  • Blood & clotting

    13.4%
    Factor Xa inhibitor10.2%
    Eliquis80%Xarelto21%
    Part D<11 patients
    P2Y12 inhibitor3.2%
    Clopidogrel65%Brilinta35%
    Part D<11 patients
  • Metabolism & gastrointestinal

    4.5%
    SGLT2 inhibitor3.4%
    Jardiance100%
    Part D16 patients
    GLP-1 receptor agonist1.1%
    Trulicity100%
    Part D<11 patients
Where care is delivered (Part B)53.9% facility · 46.1% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”